Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Tramadol hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for These tablets have been prescribed for you to relieve moderate to severe pain over a period of 24 hours. They contain the active ingredient tramadol which belongs to a class of medicines called opioids, which are 'pain relievers'. This medicine has been prescribed for you and should not be given to anyone else. Opioids can cause addiction and you may get withdrawal symptoms if you stop taking Zydol XL tablets suddenly. Your prescriber should have explained how long you will be taking them for and when it is appropriate to stop, how to do this safely. These tablets are only for use in adults and adolescents over 12 years of age.
e Zydol XL tablets Do not take Zydol XL tablets:
Warnings and precautions Talk to your prescriber before taking these tablets if you:
If your child is given these tablets after an operation they will be monitored closely to ensure that they are not breathing more slowly or weakly than usual (respiratory depression). If you notice that your child is breathing slowly or weakly after an operation, tell their doctor or nurse immediately. Use in children with breathing problems Tramadol is not recommended in children with breathing problems, since any side effects of tramadol may be worse in these children. Other medicines and Zydol XL tablets Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Using Zydol XL tablets at the same time as other medicines that slow down the central nervous system can cause slow or difficulty breathing (respiratory depression), severe sleepiness, loss of consciousness and death. These medicines include:
• • • • •
digoxin, a medicine used to treat heart failure or an irregular heart beat; other strong analgesics or 'painkillers' (such as buprenorphine, nalbuphine and pentazocine); gabapentin or pregabalin to treat epilepsy or pain due to nerve problems (neuropathic pain); certain medicines to prevent your blood clotting or to help thin your blood (known as coumarin anticoagulants, for example warfarin); ondansetron, a medicine used to treat nausea and vomiting.
Zydol XL tablets and alcohol Drinking alcohol whilst taking Zydol XL tablets may make you feel more sleepy or increase the risk of serious side effects such as shallow breathing with a risk of stopping breathing, and loss of consciousness. It is recommended that you do not drink alcohol while you are taking Zydol XL tablets. Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking these tablets. Pregnancy Do not take these tablets if you are pregnant or think you might be pregnant unless you have discussed this with your prescriber and the benefits of treatment are considered to outweigh the potential harm to the baby. Depending on the dose and duration of treatment with tramadol, slow and shallow breathing (respiratory depression) may occur in the newborn infant. If you use these tablets during pregnancy your baby may become dependent and experience withdrawal symptoms after the birth which may need to be treated. Withdrawal symptoms may include high-pitched crying, irritability and restlessness, shaking (tremor), feeding difficulties and sweating. Breast-feeding Do not take these tablets while you are breast-feeding as tramadol passes into breast milk and will affect your baby. Driving and using machines These tablets may cause a number of side effects such as drowsiness, blurred vision and dizziness which could affect your ability to drive or use machinery (see section 4 'Possible side effects' for a full list of side effects). These are usually most noticeable when you first start taking the tablets, or when changing to a higher dose.
Zydol XL tablets Always take these tablets exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Before starting treatment and regularly during treatment, your doctor will discuss with you what you may expect from using Zydol XL, when and how long you need to take it, when to contact your doctor, and when you need to stop it (see also section 2). The dosage should be adjusted to the intensity of your pain and your individual pain sensitivity. In general the lowest pain-relieving dose should be taken. Your prescriber should have discussed with you how long the course of tablets will last. They will arrange a plan for stopping treatment. This will outline how to gradually reduce the dose and stop taking the medicine. Adults and adolescents over 12 years of age The usual starting dose is one 150 mg tablet once a day. However, your doctor will prescribe the dose required to treat your pain. Do not exceed the dose recommended by your doctor. If you find that you are still in pain whilst taking these tablets discuss this with your doctor. Swallow your tablets whole with water. Do not crush, dissolve or chew them. Zydol XL tablets are designed to work properly over 24 hours when swallowed whole. If a tablet is broken, crushed, dissolved or chewed, the entire 24‐hour dose may be absorbed rapidly into your body. This can be dangerous, causing serious problems such as an overdose, which may be fatal. You should take your tablets at the same time every day. For instance, if you take a tablet at 8 o'clock in the morning, you should take your next tablet at 8 o'clock the next morning. Elderly patients In elderly patients (above 75 years) it may take longer for tramadol to leave the body. If this applies to you, your doctor may recommend prolonging the interval between doses. Severe liver or kidney disease (insufficiency)/dialysis patients In patients with severe liver and/or kidney insufficiency it may take longer for tramadol to leave the body. If this applies to you, your doctor may recommend prolonging the interval between doses. Children under 12 years of age Children under 12 years of age should not take the tablets. If you take more Zydol XL tablets than you should or if someone accidentally swallows your tablets Call your doctor or local hospital immediately. People who have taken an overdose may feel very sleepy, sick or dizzy. They may have seizures, fits or convulsions. They may also have breathing difficulties leading to unconsciousness or even death and may need emergency treatment in hospital. When seeking medical attention make sure that you take this leaflet and any remaining tablets with you. If you forget to take Zydol XL tablets If you remember within 10 hours of the time your tablet was due, take your tablet straight away. Take your next tablet at your normal time. If you are more than 10 hours late, please call your doctor for advice. Do not take a double dose to make up for a forgotten tablet. If you stop taking Zydol XL tablets
Do not suddenly stop taking this medicine. If you want to stop taking this medicine, discuss this with your prescriber first. They will tell you how to do this, usually by reducing the dose gradually so that any unpleasant withdrawal effects are kept to a minimum. Withdrawal symptoms such as restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, shaking, shivering or sweating may occur if you suddenly stop taking this medicine. If you have any further questions on the use of these tablets, ask your doctor or pharmacist.
Like all medicines, these tablets can cause side effects, although not everybody gets them. All medicines can cause allergic reactions, although serious allergic reactions are rare. Tell your doctor immediately if you get any sudden wheeziness, difficulties in breathing, swelling of the eyelids, face or lips, rash or itching especially those covering your whole body. These may be signs of a serious allergic reaction. The most serious side effect is a condition where you breathe more slowly or weakly than usual (respiratory depression) and can lead to severe sleepiness and loss of consciousness. This side effect may affect up to 1 in 1,000 people and is more likely to occur when taking certain other medicines (see section 2 'Other medicines and Zydol XL tablets'). Tell your doctor immediately if this happens to you. You may wish to ask your friends, family or caregivers to monitor you for these signs and symptoms. In patients treated with Zydol XL tablets the following other side effects have been reported: Very common (may affect more than 1 in 10 people)
• • • • • • • • • • • • • • • • • •
tingling, pricking or numbness of the skin, impaired judgement, agitation, changes in the way you perceive things around you (sensory disturbance); blurred vision; seeing or hearing things that are not real (hallucinations); nightmares; mood changes, unpleasant or uncomfortable moods or a feeling of extreme happiness; changes in activity levels; confusion; problems with recognition, changes in thinking, memory and behaviour; seizures, fits or convulsions; high blood pressure; shortness of breath, difficulty in breathing or wheezing; worsening of asthma; decreased appetite; diarrhoea; difficulty in passing urine, pain when urinating; muscle weakness; flushing of the skin; slow heartbeat.
Very rare (may affect up to 1 in 10,000 people)
If you notice any of the following signs whilst taking Zydol XL, it could be a sign that you have become addicted.
Zydol XL tablets Keep these tablets out of the sight and reach of children. Store this medicine in a safe and secure storage space, where other people cannot access it. It can cause serious harm and be fatal to people when it has not been prescribed for them. Do not take these tablets after the expiry date which is stated on the blister and carton. The expiry date refers to the last day of that month. Do not store your tablets above 30 ̊C. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Zydol XL tablets contain The active ingredient is tramadol hydrochloride. Each tablet contains 400 mg of tramadol hydrochloride. The other ingredients are hydrogenated vegetable oil, talc, magnesium stearate, lactose monohydrate, macrogol, hypromellose (E464), titanium dioxide (E171). What Zydol XL tablets look like and the contents of the pack They are white, film-coated, oval shaped tablets marked T followed by the strength (e.g. 400). The tablets are approximately 19 mm in length. In each box there are 30 tablets. Marketing Authorisation Holder and Manufacturer The tablets are made by Grünenthal GmbH, Zieglerstr. 6, 52078 Aachen, Germany for the marketing authorisation holder Napp Pharmaceuticals Limited, Cambridge Science Park, Milton Road, Cambridge CB4 0GW, UK. Zydol XL 400 mg tablets are supplied by Grünenthal Ltd, TOR Building, Saint Cloud Way, Maidenhead, Berkshire, SL6 8BN, U.K. This leaflet is also available in large print, Braille or as an audio CD. To request a copy, please call the RNIB Medicine Information line (free of charge) on: 0800 198 5000 You will need to give details of the product name and reference number. These are as follows: Product name: Zydol XL prolonged release tablets
Reference number: 16950/0092 This leaflet was last revised in January 2025 Zydol® XL tablets are protected by European Patent (UK) No. 0699436 and 0654263. ® ZYDOL is a registered trademark of Grünenthal GmbH. © 2009 – 2025 Napp Pharmaceuticals Limited
Zydol XL 400 mg prolonged-release Tablets comes as tablet containing 400mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Zydol XL 400 mg prolonged-release Tablets is tramadol hydrochloride.
This leaflet reproduces the patient information leaflet approved for Zydol XL 400 mg prolonged-release Tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Treatment of moderate to severe pain.
These tablets are indicated in adults and adolescents aged 12 years and above.
Route of administration
Oral use
Posology
The dose should be adjusted to the intensity of the pain and the sensitivity of the individual patient. The lowest effective correct dose for analgesia should generally be selected. The correct dosage per individual patient is that which controls the pain with no or tolerable side effects for a full 24 hours. Patients transferring from immediate release tramadol preparations should have their total daily dose calculated, and start on the nearest dose in the ZYDOL XL range. It is recommended that patients are slowly titrated to higher doses to minimise transient side effects. The need for continued treatment should be assessed at regular intervals as withdrawal symptoms and dependence have been reported (see section 4.4). A total daily dose of 400 mg should not be exceeded except in special clinical circumstances.
Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with tramadol in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).
Adults and children over 12 years:
The usual initial dose is one 150 mg tablet daily. If pain relief is not achieved, the dosage should be titrated upwards until pain relief is achieved.
Geriatric patients:
A dose adjustment is not usually necessary in patients up to 75 years without clinically manifest hepatic or renal insufficiency. In elderly patients over 75 years elimination may be prolonged. Therefore, if necessary the dosage interval is to be extended according to the patient's requirements.
Renal insufficiency/dialysis and hepatic impairment:
In patients with renal and/or hepatic insufficiency the elimination of tramadol is delayed. In these patients prolongation of the dosage intervals should be carefully considered according to the patient's requirements.
As tramadol is only removed very slowly by haemodialysis or by haemofiltration, post-dialysis administration to maintain analgesia is not usually necessary.
Paediatric population under 12 years of age:
ZYDOL XL has not been studied in children. The safety and efficacy of ZYDOL XL has not been established and the product should not be used in children.
Method of administration
These tablets should be taken at 24-hourly intervals and must be swallowed whole and not broken, crushed or chewed
Treatment goals and discontinuation
Before initiating treatment with ZYDOL XL, a treatment strategy including treatment duration and treatment goals, and a plan for end of the treatment, should be agreed together with the patient, in accordance with pain management guidelines. During treatment, there should be frequent contact between the physician and the patient to evaluate the need for continued treatment, consider discontinuation and to adjust dosages if needed. When a patient no longer requires therapy with tramadol, it may be advisable to taper the dose gradually to prevent symptoms of withdrawal. In absence of adequate pain control, the possibility of hyperalgesia, tolerance and progression of underlying disease should be considered (see section 4.4).
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Acute intoxication with alcohol, hypnotics, centrally acting analgesics, opioids or psychotropic drugs. Tramadol should not be administered to patients who are receiving monoamine oxidase inhibitors or within two weeks of their withdrawal.
Tramadol must not be used for narcotic withdrawal treatment.
Tolerance and opioid use disorder (abuse and dependence)
Tolerance, physical and psychological dependence, and opioid use disorder (OUD) may develop upon repeated administration of opioids such as tramadol even at therapeutic doses. Repeated use of tramadol can lead to opioid use disorder (OUD). A higher dose and longer duration of opioid treatment can increase the risk of developing OUD. Abuse or intentional misuse of tramadol may result in overdose and/or death. The risk of developing OUD is increased in patients with a personal or a family history (parents or siblings) of substance use disorders (including alcohol use disorder), in current tobacco users or in patients with a personal history of other mental health disorders (e.g. major depression, anxiety and personality disorders).
Before initiating treatment with tramadol and during the treatment, treatment goals and a discontinuation plan should be agreed with the patient (see section 4.2). Before and during treatment the patient should also be informed about the risks and signs of OUD. A comprehensive patient history should be taken to document concomitant medications, including over-the-counter medicines and medicines obtained on-line, and past and present medical and psychiatric conditions. Additional support and monitoring may be necessary when prescribing for patients at risk of opioid misuse.
Patients will require monitoring for signs of drug-seeking behaviour (e.g. too early requests for refills). If these signs occur, patients should be advised to contact their physician. This includes the review of concomitant opioids and psycho-active drugs (like benzodiazepines). For patients with signs and symptoms of OUD, consultation with an addiction specialist should be considered.
Tolerance
Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of pain control as initially experienced. Patients may also supplement their treatment with additional pain relievers. These could be signs that the patient is developing tolerance. The risks of developing tolerance should be explained to the patient.
Overuse and misuse may result in overdose and/or death. It is important that patients only use medicines that are prescribed for them at the dose they have been prescribed and do not give this medicine to anyone else.
The clinical need for analgesic treatment should be reviewed regularly.
Drug withdrawal syndrome
Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.
The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.
If women take this drug during pregnancy, there is a risk that their newborn infants will experience neonatal withdrawal syndrome.
Hyperalgesia
Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain. This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality. Symptoms of hyperalgesia may resolve with a reduction of opioid dose.
Tramadol is not suitable as a substitute in opioid-dependent patients. Although it is an opioid agonist, tramadol cannot suppress morphine withdrawal symptoms.
Tramadol should be used with caution in patients with head injury, intracranial lesions, increased intracranial pressure, severe impairment of hepatic or renal function, in patients in shock or with a reduced level of consciousness of uncertain origin, and with constipation.
The primary risk of opioid excess is respiratory depression.
Care should be taken when treating patients with respiratory depression, or if concomitant CNS depressant drugs (see section 4.5) are being administered, as the possibility of respiratory depression cannot be excluded in these situations. At therapeutic doses respiratory depression has infrequently been reported.
Concomitant use of tramadol and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe tramadol concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible.
The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).
Serotonin syndrome
Serotonin syndrome, a potentially life-threatening condition, has been reported in patients receiving tramadol in combination with other serotonergic agents or tramadol alone (see sections 4.5, 4.8 and 4.9). If concomitant treatment with other serotonergic agents is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose escalations. Symptoms of serotonin syndrome may include mental status changes, autonomic instability, neuromuscular abnormalities and/or gastrointestinal symptoms. If serotonin syndrome is suspected, a dose reduction or discontinuation of therapy should be considered depending on the severity of the symptoms. Withdrawal of the serotonergic drugs usually brings about a rapid improvement.
Sleep-related breathing disorders
Opioids can cause sleep-related breathing disorders including central sleep apnoea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion In patients who present with CSA, consider decreasing the total opioid dosage.
Convulsions have been reported at therapeutic doses and the risk may be increased at doses exceeding the usual upper daily dose limit. Patients with a history of epilepsy or those susceptible to seizures should only be treated with tramadol if there are compelling reasons. The risk of convulsions may increase in patients taking tramadol and concomitant medication that can lower the seizure threshold (see section 4.5). Tramadol should therefore be used with caution in patients prone to convulsive disorders.
CYP2D6 metabolism
Tramadol is metabolised by the liver enzyme CYP2D6. If a patient has a deficiency or is completely lacking this enzyme an adequate analgesic effect may not be obtained. Estimates indicate that up to 7% of the Caucasian population may have this deficiency. However, if the patient is an ultra-rapid metaboliser there is a risk of developing side effects of opioid toxicity even at commonly prescribed doses.
General symptoms of opioid toxicity include confusion, somnolence, shallow breathing, small pupils, nausea, vomiting, constipation and lack of appetite. In severe cases this may include symptoms of circulatory and respiratory depression, which may be life threatening and very rarely fatal. Estimates of prevalence of ultra-rapid metabolisers in different populations are summarised below:
Population
African/Ethiopian
African American
Asian
Caucasian
Greek
Hungarian
Northern European
Prevalence %
29%
3.4% to 6.5%
1.2% to 2%
3.6% to 6.5%
6.0%
1.9%
1% to 2%
This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Adrenal insufficiency
Opioid analgesics may occasionally cause reversible adrenal insufficiency requiring monitoring and glucocorticoid replacement therapy. Symptoms of acute or chronic adrenal insufficiency may include e.g. severe abdominal pain, nausea and vomiting, low blood pressure, extreme fatigue, decreased appetite, and weight loss.
Post-operative use
Prolonged release opioids should not be used for acute post-operative pain owing to the increased risk of persistent post-operative opioid use (PPOU) and opioid-induced ventilatory impairment (OIVI).
Paediatric Population
Post-operative use in children
There have been reports in the published literature that tramadol given post-operatively in children after tonsillectomy and/or adenoidectomy for obstructive sleep apnoea, led to rare, but life threatening adverse events. Extreme caution should be exercised when tramadol is administered to children for post-operative pain relief and should be accompanied by close monitoring for symptoms of opioid toxicity including respiratory depression.
Children with compromised respiratory function
Tramadol is not recommended for use in children in whom respiratory function might be compromised including neuromuscular disorders, severe cardiac or respiratory conditions, upper respiratory or lung infections, multiple trauma or extensive surgical procedures. These factors may worsen symptoms of opioid toxicity.
The concomitant use of opioids with sedative medicines such as benzodiazepines or related drugs increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4). Drugs which depress the CNS include but are not limited to: other opioids (including antitussives and substitution therapy), anxiolytics, hypnotics and sedatives (including benzodiazepines), antipsychotics, antidepressants, phenothiazines, barbiturates and alcohol.
The concomitant use of ZYDOL XL with gabapentinoids (gabapentin and pregabalin) may result in respiratory depression, hypotension, profound sedation, coma or death.
Tramadol can induce convulsions and increase the potential for selective serotonin re-uptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, antipsychotics and other seizure threshold-lowering medicinal products (such as bupropion, mirtazapine, tetrahydrocannabinol) to cause convulsions.
Concomitant therapeutic use of tramadol and serotonergic drugs, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), MAO inhibitors (see section 4.3), tricyclic antidepressants and mirtazapine may cause serotonin syndrome, a potentially life-threatening condition (see sections 4.4 and 4.8).
Simultaneous treatment with carbamazepine may shorten the analgesic effect as a result of a reduction in serum levels of tramadol and its active metabolite.
Co-administration with cimetidine is associated with a small prolongation of the half-life of tramadol, but this is not clinically relevant.
Co-administered ritonavir may increase serum concentrations of tramadol resulting in tramadol toxicity.
Digoxin toxicity has occurred rarely during co-administration of digoxin and tramadol.
Mixed agonists/antagonists (e.g. buprenorphine, nalbuphine, pentazocine); The analgesic effect of tramadol, which is a pure agonist, may be reduced and a withdrawal syndrome may occur.
There have been isolated reports of interaction with coumarin anticoagulants resulting in an increased INR and so care should be taken when commencing treatment with tramadol in patients on anticoagulants.
The analgesic effect of tramadol is in part mediated by inhibition of the re-uptake of norepinephrine and enhancement of the release of serotonin (5-HT). In studies the pre- or postoperative application of the antiemetic 5-HT3 antagonist ondansetron increased the requirements of tramadol in patients with postoperative pain.
Pregnancy
There are no adequate data from the use of tramadol in pregnant women. Animal studies have shown reproductive toxicity, but not teratogenic effects (see section 5.3). Tramadol crosses the placental barrier. Regular use during pregnancy may cause drug dependence in the foetus, leading to withdrawal symptoms in the neonate. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.
Administration during labour may depress respiration in the neonate and an antidote for the child should be readily available. Tramadol administered before or during birth does not affect uterine contractility.
Breastfeeding
Tramadol is secreted in breast milk and may cause respiratory depression in the infant. Approximately 0.1% of the maternal dose of tramadol is excreted in breast milk. In the immediate post-partum period, for maternal oral daily dosage up to 400 mg, this corresponds to a mean amount of tramadol ingested by breast-fed infants of 3% of the maternal weight-adjusted dosage. For this reason tramadol should not be used during lactation or alternatively, breastfeeding should be discontinued during treatment with tramadol. Discontinuation of breastfeeding is generally not necessary following a single dose of tramadol.
Tramadol may cause drowsiness, blurred vision and dizziness which may be enhanced by alcohol or other CNS depressants. If affected, the patient should not drive or operate machinery.
This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:
• The medicine is likely to affect your ability to drive.
• Do not drive until you know how the medicine affects you.
• It is an offence to drive while you have this medicine in your body over a specified limit unless you have a defence (called the 'statutory defence').
• This defence applies when:
o
The medicine has been prescribed to treat a medical or dental problem; and
o
You have taken it according to the instructions given by the prescriber and in the information provided with the medicine.
• Please note that it is still an offence to drive if you are unfit because of the medicine (i.e. your ability to drive is being affected).
Details regarding a new driving offence concerning driving after drugs have been taken in the UK may be found here: https://www.gov.uk/drug-driving-law.
The following frequency categories form the basis for classification of the undesirable effects:
Very common (≥1/10)
Common (≥1/100 to <1/10)
Uncommon (≥1/1,000 to <1/100)
Rare (≥1/10,000 to <1/1,000)
Very rare (<1/10,000)
Not known (cannot be estimated from the available data)
Very Common
Common
Uncommon
Rare
Very Rare
Not known
Immune system disorders
Hypersensitivity
Anaphylactic and anaphylactoid responses
Metabolism and nutrition disorders
Decreased appetite
Hypoglycaemia
Psychiatric disorders
Hallucinations
Nightmare
Mood altered
Euphoric mood
Dysphoria
Decreased activity
Illusion
Confusional state
Drug dependence (see section 4.4)
Nervous system disorders
Dizziness
Somnolence
Headache
Paraesthesia
Psychomotor hyperactivity
Cognitive disorder
Sensory disturbance
Judgement impaired
Seizure
Sleep apnoea syndrome
Hyperalgesia
Serotonin syndrome
Eye disorders
Blurred vision
Cardiac disorders
Palpitations
Tachycardia
Bradycardia
Vascular disorders
Orthostatic hypotension
Hypotension
Circulatory collapse
Hypertension
Flushing
Respiratory, thoracic and mediastinal disorders
Dyspnoea
Worsening of asthma
Respiratory depression.
Bronchospasm
Wheezing
Hiccups
Gastro-intestinal disorders
Nausea
Vomiting
Dry mouth
Retching
Constipation
Abdominal discomfort
Diarrhoea
Hepatobiliary disorders
Hepatic enzyme increased
Skin and subcutaneous tissue disorders
Hyperhidrosis
Pruritus
Rash
Urticaria
Angioedema
Musculoskeletal and connective tissue disorders
Muscular weakness
Renal and urinary disorders
Micturition disorders
Dysuria
Urinary retention
General disorders and administration site conditions
Drug Withdrawal syndrome which may include:
• agitation;
• anxiety;
• nervousness;
• insomnia;
• hyperkinesia;
• tremor;
• gastrointestinal symptoms.
Asthenia
Drug withdrawal syndrome neonatal
Drug tolerance
Drug dependence
Repeated use of ZYDOL XL can lead to drug dependence, even at therapeutic doses. The risk of drug dependence may vary depending on a patient's individual risk factors, dosage, and duration of opioid treatment (see section 4.4).
Paediatric population
Neonatal drug withdrawal syndrome may occur in infants born to mothers taking tramadol, however the frequency is unknown (see section 4.6).
As these tablets are made using an insoluble matrix from which the active ingredient is gradually released, the patient may notice the matrix in their faeces.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms
Symptoms of overdosage are typical of other opioid analgesics, and include miosis, vomiting, circulatory collapse, sedation and coma, seizures and respiratory depression. Serotonin syndrome has also been reported. In severe cases tramadol overdose may result in a fatal outcome. Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.
Management
A patent airway must be maintained. The pure opioid antagonists such as naloxone are specific antidotes against symptoms from opioid overdose induced by tramadol, though it will not antagonise tramadol's inhibitory effects on MAO reuptake or serotonin releasing effects. Other supportive measures should be employed as needed. Naloxone should be used to reverse respiratory depression; fits can be controlled with diazepam. In case of oral intake of overdose, consider activated charcoal if the patient presents within one hour of ingestion of tramadol, provided the patient's airway can be protected.
Although it may seem reasonable to assume that later administration of activated charcoal may be beneficial for prolonged-release preparations and drugs that slow gastric emptying, there is no clinical trial evidence to support this.
Tramadol is minimally eliminated from the serum by haemodialysis or haemofiltration. Therefore treatment of acute intoxication with tramadol with haemodialysis or haemofiltration alone is not suitable for detoxification.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Zydol XL 400 mg prolonged-release Tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.